Multi-drug Resistant Organism Module 
  | 
Active Surveillance Culturing Option 
  | 
|   |   |   |   |   |   |   |   |   | ASC* Process and Outcome Measures 
  | 
Location 
  | Organism 
  | ASC-Timing 
  | ASC-Eligible 
  | Incidence 
  | Prevalence 
  | 
_____________ 
  | _________ 
  | Adm 
  | Both 
  | All 
  | NHx 
  |  
  |  
  | 
_____________ 
  | _________ 
  | Adm 
  | Both 
  | All 
  | NHx 
  |  
  |  
  | 
_____________ 
  | _________ 
  | Adm 
  | Both 
  | All 
  | NHx 
  |  
  |  
  | 
_____________ 
  | _________ 
  | Adm 
  | Both 
  | All 
  | NHx 
  |  
  |  
  | 
_____________ 
  | _________ 
  | Adm 
  | Both 
  | All 
  | NHx 
  |  
  |  
  | 
Process and Laboratory-identified MDRO Event Monitoring Option 
  | 
Location 
  | Organism 
  | **LIME 
  | HH 
  | GG 
  |   |   |   |   |   | 
_____________ 
  | _________ 
  |  
  |  
  |  
  |   |   |   |   |   | 
_____________ 
  | _________ 
  |  
  |  
  |  
  |   |   |   |   |   | 
_____________ 
  | _________ 
  |  
  |  
  |  
  |   |   |   |   |   | 
_____________ 
  | _________ 
  |  
  |  
  |  
  |   |   |   |   |   | 
_____________ 
  | _________ 
  |  
  |  
  |  
  |   |   |   |   |   | 
Patient Influenza Vaccination Module 
  | 
Method A: 
  |  
  |   |   |   |   |   |   |   |   | 
Method B: 
  |  
  | Denominator Level: (Circle One) 
  | Summary 
  | Patient Level 
  |   |   |   |   | 
|   |   |   |   |   |   |   |   |   |   | 
|   |